MBX Biosciences, Inc. (MBX) Stock

About MBX Biosciences, Inc.

MBX Biosciences, Inc. is led by CEO Peter Kent Hawryluk, employs 43 people, headquartered in US, publicly traded since 2000.

MBX Biosciences, Inc. (MBX) stock trades at $48.50 with a market capitalization of $2.34B. The stock is valued at a negative price-to-earnings (P/E) ratio of -24.38, reflecting a net loss over the last twelve months, price-to-book of 6.81, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $12.94 and $72.64, and currently trades 33.2% below its 52-week high.

On profitability, MBX Biosciences, Inc. generates a return on equity (ROE) of -26.01% (negative, reflecting a net loss), return on capital employed of -28.60%.

MBX Biosciences, Inc. by the numbers, 2022–2025

Between 2022 and 2025 MBX Biosciences, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-87.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-105.0M.

Borrowings stand at $1.0M, cash from operations was $-80.0M in the latest year, positive in 0 of the last 4.

Return on equity has averaged 14.7% over five years, and was -23.6% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

MBX Biosciences, Inc. (MBX) — frequently asked questions